Registry of Lobbyists
Total Number of Communication Reports: 0
Monthly communication reports in the last 6 months: 0
| Subject matters | Details | Categories |
|---|---|---|
|
Budget, Health, Industry
|
Common Drug Review and the pan-Canadian Oncology Drug Review, as they relate to health technology assessments and drug product reimbursement recommendations.
|
Policies or Program
|
|
Budget, Health, Industry
|
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
|
Policies or Program
|
|
Budget, Health, Industry, Intellectual Property
|
Food and Drugs Act and Regulations, as they relate to drug export and cross-border trade.
|
Legislative Proposal, Bill or Resolution
|
|
Budget, Health, Industry, Research and Development
|
Food and Drugs Act and Regulations, as they relate to the provision of data exclusivity for innovative drug products.
|
Legislative Proposal, Bill or Resolution
|
|
Budget, Health, Industry, Research and Development
|
Food and Drugs Act and Regulations, as they relate to the review and approval of new drug submissions and post market surveillance of drug products.
|
Legislative Proposal, Bill or Resolution
|
|
Health, Industry, Research and Development
|
Food and Drugs Act Modernization initiative, including the Regulatory Review of Drugs and Devices.
|
Legislative Proposal, Bill or Resolution
|
|
Health, Industry, Research and Development, Science and Technology
|
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.
|
Policies or Program
|
|
Budget, Health, Industry, Research and Development, Science and Technology
|
Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda, the Biomanufacturing and Life Sciences Strategy and other government policies and programs related to incentivizing research and development activities in Canada.
|
Policies or Program
|
|
Budget, Health, Industry, Research and Development, Science and Technology
|
National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases and incentives for development of the treatments for rare diseases.
|
Policies or Program
|
|
Budget, Health, Industry, Intellectual Property
|
Patent Act and Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property and approval for therapeutic products.
|
Legislative Proposal, Bill or Resolution
|
|
Budget, Health, Industry, International Trade
|
Regulations regarding the exportation of medicines packaged and labelled for the Canadian market to countries other than Canada.
|
Policies or Program, Regulation
|
Address:
5060 Spectrum Way Suite 505
Toronto, ON L4W 5N5
Canada
Telephone number:
855-215-2288
Ed Dybka, General Manager
Ipsen Biopharmaceuticals Canada Inc. is not a coalition.
The activities of Ipsen Biopharmaceuticals Canada Inc. are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Ipsen Biopharmaceuticals Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
WILLIAM DEMPSTER | Public offices held
Firm: 3Sixty Public Affairs Inc. / 3Sixty Public Affairs Inc.